Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

about

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Item

http://www.wikidata.org/entity/Q52724679

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@en

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@nl

type

Item

label

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@en

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@nl

prefLabel

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@en

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

@nl

P1476

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

@en

P2093

Leonardo A Meza-Zepeda

http://www.w3.org/2001/XMLSchema#string

Ola Myklebost

http://www.w3.org/2001/XMLSchema#string

Sarina Gouravan

http://www.w3.org/2001/XMLSchema#string

P2860

The epidemiology of sarcoma

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

P31

scholarly article

P356

10.3390/IJMS19040969

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Else Munthe

Eva Wessel Stratford

P577

2018-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29570692

http://www.w3.org/2001/XMLSchema#string

P932

5979358

http://www.w3.org/2001/XMLSchema#string